Recently, Qiyu Biotechnology (Shanghai) Co., Ltd. received tens of millions of yuan of pre-B round investment from New Henglida Capital and other related institutions.

Founded in July 2017, Qiyu Biotechnology (Shanghai) Co., Ltd. is an innovative macromolecule biomedical R&D company, focusing on the research and development of innovative macromolecule biologics. The goal of Qiyu Bio is to develop new therapeutic drugs for refractory cancer, autoimmune diseases and metabolic diseases, and master an independent innovation platform for the research and development of multiple antibody drugs, including: hybridoma antibody humanization platform, bacteriophage display technology platform, single-domain antibody platform and antibody engineering platform. Qiyu Biotech will rely on its own platform to develop new biological drugs with its own intellectual property rights, and currently has nearly ten pipeline projects under development, most of which are aimed at solid tumors.

As the core category of innovative drugs, antibody drugs are experiencing a period of rapid development, setting off a capital boom at home and abroad, and their market volume has reached hundreds of billions of dollars. Among the top ten drugs sold in the world, antibody drugs account for more than half. It is predicted that by 2030, the domestic antibody drug market will exceed 3000 billion yuan.

The funding will be used primarily to advance the preclinical development of the Q-1802 and Q-1801 programs. Q-1802 is a dual-target immunotherapy for solid tumors such as gastric cancer, and has completed three batches of pilot production, and is expected to complete the Sino-US double report this year. The Q-1801 project is a bispecific antibody drug targeting the tumor microenvironment signaling pathway, and the clinical application is expected to be completed in 2021.

Xiangdong Qu, the founder of Qiyu Biologics, has 20 years of experience in new drug research and development at home and abroad, and has rich experience in protein new drug development and management in the United States from March 1999 to early 3 for Cell Therapeutics Inc., Eli Lilly and Amgen. The core team of Qiyu Biotech is composed of antibody engineering and antibody process scientists, many of whom have more than 2012 years of experience in antibody engineering.